0001104659-23-116010.txt : 20231109 0001104659-23-116010.hdr.sgml : 20231109 20231109075746 ACCESSION NUMBER: 0001104659-23-116010 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231109 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: EAGLE PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000827871 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36306 FILM NUMBER: 231390121 BUSINESS ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 201-326-5300 MAIL ADDRESS: STREET 1: 50 TICE BOULEVARD, SUITE 315 CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 FORMER COMPANY: FORMER CONFORMED NAME: EAGLE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19880120 8-K 1 tm2330299d2_8k.htm FORM 8-K
false 0000827871 0000827871 2023-11-09 2023-11-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 9, 2023

 

Eagle Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 001-36306 20-8179278
(State or other jurisdiction of (Commission File Number) (IRS Employer Identification No.)
incorporation)    

 

50 Tice Boulevard, Suite 315
Woodcliff Lake, NJ		   07677
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (201) 326-5300

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock (par value $0.001 per share)   EGRX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 2.02Results of Operations and Financial Condition.

 

On November 9, 2023, Eagle Pharmaceuticals, Inc., or the Company, issued a press release, or the Press Release, announcing, among other things, that it will be delaying the release of its third quarter 2023 results and related investor conference call as the Company will need more time to review potential adjustments relating to the reporting of sales of PEMFEXY®. The Company anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (“Form 10-Q”), and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended, or the Exchange Act. The Press Release also provided that the Company expects to revise its 2023 guidance downward. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit No.   Description
99.1   Press Release of the Company, dated November 09, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 9, 2023 EAGLE PHARMACEUTICALS, INC.
   
  By: /s/ Scott Tarriff
    Scott Tarriff
    Chief Executive Officer

 

 

 EX-99.1 2 tm2330299d2_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

A picture containing clipart Description generated with very high confidence

 

Eagle Delays Third Quarter 2023 Results and Conference Call

 

WOODCLIFF LAKE, NJ—November 9, 2023—Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 (the “Form 10-Q”), and expects to file its Form 10-Q  by November 14, 2023, prior to the expiration of the extension period provided by Rule 12b-25 under the Securities Exchange Act of 1934.

 

The Company requires more time to review potential adjustments relating to the reporting of sales of PEMFEXY® prior to filing its Form 10-Q. In addition, the Company expects to revise its previously disclosed 2023 full year guidance downward.

 

“We remain confident in the strength of our business and our outlook for 2024, and we look forward to reporting on our commercial portfolio, progress on our pipeline and other initiatives,” stated Scott Tarriff, President and CEO of Eagle.

 

Third Quarter Fiscal Year 2023 Earnings Conference Call

 

The Company will reschedule its third quarter 2023 financial results call at a time to be announced.

 

About Eagle Pharmaceuticals, Inc.

 

Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.

 

 

 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities law. Forward-looking statements are statements that are not historical facts. Words and phrases such as “anticipated,” “forward,” “will,” “would,” “could,” “may,” “remain,” “potential,” “prepare,” “expected,” “believe,” “plan,” “near future,” “belief,” “guidance,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, the Company’s expectations with respect to the timing of its SEC filings, including the Form 12b-25 and the Form 10-Q, and the anticipated release of financial results for the third quarter ended September 30, 2023, expectations with respect to the anticipated reporting of financial and business results, including potential adjustments related to the reporting of sales for PEMFEXY®, and statements and expectations regarding the Company’s financial projections and guidance, including anticipated financial performance for 2023, the strength of the Company’s business, pipeline and other initiatives and the potential of the Company’s pipeline and product candidates to address underserved therapeutic areas across multiple disease states. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the Company’s control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Such risks and uncertainties include, but are not limited to: the impacts of the post- COVID-19 environment and geopolitical factors such as the conflicts between Russia and Ukraine and Gaza and Israel; delay in or failure to obtain regulatory approval of the Company's or its partners’ product candidates and successful compliance with FDA, European Medicines Agency and other governmental regulations applicable to product approvals; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether the Company can successfully market and commercialize its product candidates; the success of the Company's relationships with its partners; the outcome of litigation involving any of its products or that may have an impact on any of its products; the strength and enforceability of the Company’s intellectual property rights or the rights of third parties; competition from other pharmaceutical and biotechnology companies and the potential for competition from generic entrants into the market; unexpected safety or efficacy data observed during clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the risks inherent in drug development and in conducting clinical trials; risks inherent in estimates or judgments relating to the Company’s critical accounting policies, or any of the Company’s estimates or projections, which may prove to be inaccurate; unanticipated factors in addition to the foregoing that may impact the Company’s financial and business projections and guidance and may cause the Company’s actual results and outcomes to materially differ from its projections and guidance; and those risks and uncertainties identified in the “Risk Factors” sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on March 23, 2023, the Company’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2023, filed with the SEC on May 9, 2023, and for the quarter ended June 30, 2023, filed with the SEC on August 8, 2023, and its other subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

Investor Relations for Eagle Pharmaceuticals, Inc.:

Lisa M. Wilson

In-Site Communications, Inc.

T: 212-452-2793

E: lwilson@insitecony.com

 

Public Relations for Eagle Pharmaceuticals, Inc.:
Faith Pomeroy-Ward
T: 817-807-8044
E: faith@eagleus.com

 

 

 

 

 GRAPHIC 3 tm2330299d2_ex99-1img001.jpg GRAPHIC begin 644 tm2330299d2_ex99-1img001.jpg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end EX-101.SCH 4 egrx-20231109.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 egrx-20231109_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 egrx-20231109_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 09, 2023
Entity File Number 001-36306
Entity Registrant Name Eagle Pharmaceuticals, Inc.
Entity Central Index Key 0000827871
Entity Tax Identification Number 20-8179278
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 50 Tice Boulevard
Entity Address, Address Line Two Suite 315
Entity Address, City or Town Woodcliff Lake
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07677
City Area Code 201
Local Phone Number 326-5300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock (par value $0.001 per share)
Trading Symbol EGRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2330299d2_8k_htm.xml IDEA: XBRL DOCUMENT 0000827871 2023-11-09 2023-11-09 iso4217:USD shares iso4217:USD shares false 0000827871 8-K 2023-11-09 Eagle Pharmaceuticals, Inc. DE 001-36306 20-8179278 50 Tice Boulevard Suite 315 Woodcliff Lake NJ 07677 201 326-5300 false false false false Common Stock (par value $0.001 per share) EGRX NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://eagleus.com/role/Cover Cover Cover 1 false false All Reports Book All Reports egrx-20231109.xsd egrx-20231109_lab.xml egrx-20231109_pre.xml tm2330299d2_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2330299d2_8k.htm": { "nsprefix": "egrx", "nsuri": "http://eagleus.com/20231109", "dts": { "schema": { "local": [ "egrx-20231109.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "egrx-20231109_lab.xml" ] }, "presentationLink": { "local": [ "egrx-20231109_pre.xml" ] }, "inline": { "local": [ "tm2330299d2_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://eagleus.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330299d2_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2330299d2_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://eagleus.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-116010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-116010-xbrl.zip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
$B7Q=?;H*;0SI"NP;= M\$'8&G0MQP&J9&$Y.(7%S\=?Y)#*[)7$4CM])1PC841KMNYCW=V#BL&_,/_VZ-*/!9$\Q_@4/#'C %Y>#K1J#E9&KZ^!M0 M2P,$% @ -C]I5T6#XC']"@ @(8 !4 !E9W)X+3(P,C,Q,3 Y7VQA M8BYX;6S-G5UOX[@5AN\+]#]PW9L6&,>)@Q9(=F87&4^R,#:;9&//;-M%L: E MQA%"DP$E)_:_+RF)LD3Q2$J*DIR+&8_X'NJE^)BDOHX__KC;4/1"1)IP]FET MQRQ[3L\GD]?7UR/&7_ K%T_I4<0WPRI< M9#C;IE5MQ[OC\D\1_I$F[.E<_;7"*4'R>+'T?))4IHH$D;EMD=!'NQFJ! 3%3]A9(TS$JL=G:D=G?Q#[>@OY>9K MO")TA)12\@&VZZQ15QDT<6WVCHB$QY?L?:[-:$_VY7='9/]# ^KQSINPY!FF M[S)?CW1N^X:\[X@?XMP?:3G.D_<=Z5KD_\5VUK;\YL-K/ZY4;;R6GQH6R2Z3 M$QB)M4E51<<(G.\AGQC*NJO:>=2HEZK1G(MVV]7,F->9DNAHS5\F,4EDW=-3 M]6&L/N3-EO_Y8\;E2N!BE68"1YFN*6_&IY&E?&):4LH+H7UA$?4TKE1,(BZG MIN=L3(O#6(0_"+ZQ[K9L-;<4_D%757QQ6.0N *,-F2 IWXJ(O*E7ZFZAHU0Z MVE"I4$LJPL9?%Z,?<@WZ7:O^\W%RJ,5!1\LET'9#6+:4-5I:T"QVUP8Q@"]ZZ&_T[8Y%UC%04 SQ"$X6]2#4!7EB:,+QK:8WI-G+KKP:)SPMVUW\5.)@ M$3(=#J0H#T,JSA-)M=L0/0RUE*[I :R:W!BRH(BQ>P-9*>0HU_N'Y)+%@Q"I M='X ,6S:\2A% <+1=-:'AE3[!.,J22-,"R]70-4#S-0)I[N9KM9$6%I7%OBB@W( MG&;"+ ^"!<"4R4 A0TJ'"J&7GM=W"5BF'F($FV/*W!)@-]FDH*D)B 2K,8"& M@S9_IM0+$3,Y,@E,YRPFNY_)'FQ72^>6"FQW60&$ >$3K=#@" 9A)I1/D&:LXB+9UY[W&'&MW( W,]X#*]0 M>J+<0C6H"4VT.D," FR(3P"S1NB'XID4Q-5[/'D%2-7@A;B+.)8'*BW_N4X8 M.0';;]6ZI:O#;I,IBS @DF!W #^E\H/^@%0,NF6A0#-]0U.G_J&9#H5F&C0T MT_= LWSE@4!S^H:FGOJ'YG0H-*=!0W/Z+FADQWL=:V;RXZU8\E?;P]F@T@LR M;:M68 ZR\'!I>>N#106H]8P*\8E)OK"Z%7>"OR0L@I?,D-P+,(!I*S6&-CQT M[ ;[^*D6Q#K.ZUA3+,I[OR1:YF>4:9JT#S&%)CQ(FL9Z!Y="[1.).YYFF/X[ M>>X\$;>+O>!A-6R%I*$,#Q6;O3Y@BA@D@WR<6)>XJAL:UE?)C')WKP!;;!U> M :X5!@&!S5'[%>#BZDDABY#N<[3U7B582*U#]^U M,F;+2OO\MB>&P1TKGJYTZ;N M<:LHB-[O($V2R%ZHBT"=;"Q)MY?RX M/YFNEDE&;2>7;8FS.0DP5\U(1GD0; "F3!;R,L0?T,GTKZN_(1WEN/MO^%)@ ME3QVL=^L. 6R3UE5KB#HL*@YL$B"0 'V9=)PPU$I18761W:JAEE+FN;Q0&T>DV1ZTO?Z.O/0WYE[OH49HBP L)=IGKH=]FTAS^ZYH@$.@PUCHI M*:5(:WV\D'"8LM;]BX"UMT7 NF<1L YQ$; >N@A8>UL$Z-T6*4+DN'2[HLD: M \D).]6NH>BP;/)AD0:%"NP/'#.J$'2(<9W1,D]QIM+SBTV^_ROYP=)*0.8J89A%":95>D3;%?'^ M$&>T##1?@=.C#X.A829;.!5A.I=A%7A(=>GZ4GKQ ,9OA-*?&7]E"X)3SDA< M7$NQW2GJUKM]8J;'=O.A&4 T"ZR1U2+K.)WA\ &0G+'KVMW MFC;>VK9J V*FTR#T#G>9\^.P-BZB/+UBF1'U>Q')"_F",UQZ ]L+R5V_5-EE MVGR;TJ8-"*%.@^#[DU6,2A6#-5/>4L:(F5QJK7G'4^*&RGWBF);%=NZ82A(0 M'C9?'1ED!-):+RPL-IC2S]LT822%)R)#Y98%J\4F"PU)0"S8? $LY%*DM5Y8 MN-P0L9;3VT^"OV:/97Y6L&V VBT;G9:;C%BE ;'2Y0]@1H>@(D:GU/4#S^Z0 M4+S(L@BWU")UC UHUF"FI0L)&,AUCRYS@.1BO29S:B> MW!Y>XC5$CE?&%H/&PKBF"((1T!:T+*[_5H"?W'G;%4VB*\HQ?)6EH7&<,:]M MSTB6=Q $1$#;%90B+Q>B7.FE_S]C]B2VSUFTOQ,\(D0]9956HU7?];>!T6Z9 M>5.3FC0-"@V(L[?X!0@\5(%J=7RHS5@^+^:IA\95-C<>/2T>L3R M]LL53.H M- 9?!>\,>@'5 2C6K2G\[/TD 60Q)_W M]^2!"/7>P9+LLL]R1T\=9Q@#8EV?O0UNCGDRUQL8!(1O=0N=ZJ6H7@%:J6?$ MRBK0[ZH2E-=B^_WR^J9K^4ENUIOD7RN<$KGEOU!+ P04 " V/VE7[B07 MB%0' #35P %0 &5GJ9*,RDN6[V3;BNB(I8)$[/+UI=Q^VH\&(U:D39$ M)(1+02];0K;>_?7S3Y']N?BEW8Z&C/+D/'HOX_9(3.7;Z#-)Z7GT@0JJB)'J M;?25\,QMD4/&J8H&,EUP:JC]HFCX/'ISTN].HG8;4.]7*A*IOCR,MO7.C5GH M\TYGN5R>"/E,EE(]Z9-8IK *QX:83&]KZZZZFY^B^ 5GXNG<_9H032/+2^CS ME6:7+=?NIMGEZ8E4LTZ_V^UU_OET.X[G-"5M)ARWF+;*4JZ6JG*]L[.S3OYM M*3U2KB:*EVV<=LKN;&NVW[* ?JKX[[K#*3='VU'\U)S1:>7 M+3I3*UMY_[37ZYZYJG_=$YGUPNZ7FKG=JA5U]II=**JI,+G36[MAKPA=&;LW MT:2LR+4/[)AAQFDWNTHO:KO]*DMM4_9CH=STH^P)E_%>X]SQEP=.RWTYIZQI M?#*3SYV$LHYS[S[D&'($]I_O>4-7$VT4B4U9$R<3RO/ZOUO-@:330*]*$H^V MQNI.[2L.^[0;LRL51U(E5%G695U$Q7N1.MXM-XK.@BA;43N>,[X-\E3)U$=G M0T)Z.KH+RC;1#,TKVW[B^C#D9%:-\T "Y-G# %KI!HOH>ZICQ1:.2PW8/260 M;Q^5;X6WAC&7Q\X#G3'77]<5=[*E;F-X7/ 4 8(_Q1PI@FZ1(G E1$;X UU( M50-^7PGD_1LF[RIO2)C_SH@R5/$UA/21& C[#29LCT,DWH^*",T<'PCP8S60 M^.^H%QX>CTC(QW/*N4O@B #MY55Z(/8_,+'[?;X"\#?/[OQN3RUP]CM%@/C_ M?"WXC]PB1>">*B83>TI7 /9'8B#U,TSJ'H>HO&]$ J6]E8+S'WS8!_:04 ^9 MC@DO>C2TVW08=X4:1#&/<@( M\3U40AFCY)HALQB^L' MC6,M%#9*9ADVB$+[D:Q&B77%IJQX%%@/W5L$RAXEK03910G!2,12+>3.[>*! MS.SQN![()#BDUQ2$A@,EWWR!=92@7"6)Q:4W?VZ9H+U0*"KEX&=$> $(V'PE MV/LOP]Z'8T?)0VMMOA+LIR_#?@K'CI*+UMK$Q#ZP'^_4HUQZGD![Q5#D*+EH MC45,X/F9YD[=*_G,BAE1==2/2D#1(Z:H8;.H.WQQDH?L[:42RALQ7:TVA\GY M7FI#^']L47_8QER)X/_98!>6*DDGZ3#4]\+IYQ-I[Z.]\#9[! MAC*L'MIH&.,WQ8SMP4"F:28V]V@\3\4\4BA>E/0O:*]AU&/)6:\?U7@/)%"P*)E=I1VD,>%F%<^) MF%'_[(5J)10P2J87,H3^&]D,U=H\4"AQGB63(7M.HLX09FA1=&C)! M1&Q3JNVZ-D]V7E\*&@"<-91 TRBW][]1SC\*N11C2K04-"DN]4-W^+U%H%% M?(988QIX3SZTPS075P;#D00B$CSGFMM(8"^2:E:F8'M0]*+LU\L[8S M!-M3 H=<69KT"H._-6/=>3%^K<@^0HU^.T$B-B])K%>NQ'';B)%<287"5$> MZB$]E#OJPDJ_T8;)WYDY5;O73WEG1C9O"TUZJ"\%C0)*N@HUC7-NW5G)'SRU M[NF@O!$3TRIC.&NFL@EG\9!+$KPNWY-!^2)FH16V4/!>$_&DLH6)U_=*QI2Z MQR=Z>[0!$B)@!="0(.:G+T*!<[M IJE;3"3CI_'B=)%RGFSQ,_*>TO77<=Z ?]#7X2:+O M.%8QG1X.AZEA-F7:O72F4"BD1]@GX74JCF+[R9*42=]?7K24/AO0I&9PAQH* MFPS2->-I,7QLG73MV+H6Z8I/@DFRZ3G0T*I.!X0[[Z>]QDA7)[9KWNOJ!%TU M;N;DS,%K>'@])@-&B_IF$&=8(;O_TKR8=G?B^T^[IAV;&KQKV@/J \14CXI MR4EY/P0DR9D2 03?4SWSY4TXA\EL)H SQYSH2K&Y0_F$XBJ;(7TIS.7IQ1S(#IE,E(A(72+414^"?XY=C1'9Z7C MM/<)K0/F4((@DNS9U5Y.$A73<)CA)-MC"XBM>-].$@X;.6E/!=,X+NV#/?Z? M9)*<:DQ7BZ3%G"/2H -6)"-U=$3J5?'+HR17'F]:?\G5LW+Y&CX0/9),+CLZ MFWW$E3Z&5O@8K' %,+G]R:CW#,\7'AG(%J /?\L#9JCPSSG5:>^Q2W7.5@%U M& )5,X 7XPK LJE>-U0V.F?C1PG^',H'AP>9%>#N?P$R5Q\SC[Y9\": 1ZO MD!];?6HS_B@_"BOH >'BV2IPJHC+M0\K.X?20N =4QT3[HQU=I+H@O0524:R M'-+6!M"EP8:D:0ZHL><]V ,$;*TKY%S57H)QJL8MG8Z+Q# -)AJU41$%EMFH M">*;IJK,$'J!7Z%CPQT +,43^9'31+M1YE==E)5D)I,$=2(&K!3 ,ZT8D8!$ M28C <3H"Z?W 8V4B49H*1>Q,Z.BOV:BJ7-K M#NQ2T)6)A4^>3IYK*K9T-683@3Z+=3>5^GF42+.#I].E8^?S9[. IJ8ZCP7X M?-NI4H>5IDL(($W;YH:!H"P8%+3,HA5!('CHDS%*6]?0/,*"2LU1<\ H=VU6 M\G6O"'T"8$%3= J$M@"^I\@+I_")(#J]>XZIP9B;!Y0;V#A/6QPKE( ZIAUJ M7IT&LSC&00U-6F6&.=",MZ9]FRZS\\8!#MHC5)@CJ*^5(1WT3$)@]X[3,!X^ M\;]7K>5,UY"Y;[HZ2U[3GO!V81@#:O5EO=6J7S5>1>]-U_TQ].XH[T,NZ9@ M9JJI+:W M9"F?*_PQE/ZLU)Q>-2_),;>H(RN3):9-,OD==?=5LFP8-[-+G#Y#M%Q;"-E#XUP%F4%8= >Z:0S7U6SFUR:HQ3^,/3J9%PO&%ZNC\[KU!W?'596,DP>>6FDX0V MU^Z_W=1N]%_T)OM.YQ,W5Z)4PZ(1N88 ?$ 5YCJ: M IGZ'JD;2NJS.:>=VHB"D<$5H:;9DY5L;U%.N,443&)5H@&E'4[ +H&BV;M_ M -?),YUU828I)>8K@-=%5'REQ+BNT55-?B^,LZA)&*2&RBF MKE.+0P80_":J/DZ00AT[:C#1"[.%$ 3+AG5.8&:S?\71)%;$#R(B#O)DVF#Y M1'6[Y8#UJ'A5W8JI+I#X6UNK.0.6+5?5]UHU++QCY<%AEFV^H.!$S=H2N(%E M9SH=@D%\51T<=45*YI:G9"Y"R5--9X "6-UXLJGR_66M>O$K7\U\R%!,Y\&: M42:9W<]*^^NEP0K2%*5!FX[J?M%*$5Q[C2!2CU]\TX;7\GG^0P19,&FB)$O) MP\Q!03XX?(L\\,->2>_B[$\XG??\BZ#5RB7A'2'J'AX07)H0V=GD)P1V7-5$ MV E&=K* I7D;Q\^=BCD8:!PW.0F*%?$HM_M1L/5FB]0&EFZ. ?,H;TC#3.U^ M/IJ#;PK9FMWUD#=P*^L"$E L+1Q4Z<_&\)MUDH7\VGUDKK"\5:M$K%I956W& MN?]QH1DL$V_13LW1U?@YKSZ7>Q^R:#$3)DIY"4BE,/+%='7V0FUU@5';FZND M5-]8C1R_FFY5+=0O?E;[1?,INT\A^2X-57@ MURN[;0Z-^!5]JS]+?45JWYRMEH\M6-%TND3ISC151=>Z77)!GQ:%)/.LV8]; MAK#_5_8UA$9@EA9$8??[%&Q_+.^+GA!3RVX=C"L]\3!107J!_JYC) M&9"KZ'0VCM37)D2A^H-F+0YW*P=5Y?HZ^U4WUR(TD1DA@CO8/SCX#>$)>&4? M 4S1+!N8K%E4)VS$%$@N7S!S Q_-^)+./V#$QOS>#I"(((UV/Y_O^YU33^L" M__[7H9PY..+;6P[3F=4W#48,$;#M8?BBN^AU"21$%.129:*.M3.K!7E?"]!V ME:'K8KEW[7&W)=WVQC?Z.^4^/ =&XW.[_[Z<[\Z9Q2!'O3!!5*YQI:\E$E3J MC9NW/Q7G=+6$=(KI[#R)4E;>3^:SDO39:BT?E\3(?F$4$ZR*)$J5/E.>1#V9 M6I">@ZW DFG'')$.T\TAT;QB\RFD\^0P>4ZZFHZ"IW&00H<9*E-!0DW"M8&K M.]1@ILOU,>$06?/N6 SU1Y@=F%8$W,(H8R^22I[]Y'6%:6YC#: ML$1E63*WHRPG47[?34C4NA,7C \7QZFVUNOCIEI\X!H^F^!%>Y%SEAN;] M*+5LJHK !S%KC0<=4_^TU!KV-8F/#WRWRA M8X&Y!7,"2,.3JZTNO9*D>ICBK;)K:M9IUP.L@+/X(XS^LG2([%K7)"]5=1OY72DE2AEAX&0(/EN^^ M[GT_+/I+47U-QN%WN,;JZ'8UR[V1O9))$J7;6O/\O MV][%MOT9Q0Q"PL5GRYQK;O]XL&KNW?Z'3MJ@-9P_9!.'1Z+4AIBK0;E*GWT% MOJ3V$W/(Q45E";ZOI4S_.^MR7LFS;J@8S3/2&1-%E#]AR!-X#B8.7\Q4)C5. M@+&0"R!4<-P]VQPZ$.B8 PO+E903E74UPSOQYI6QI#R9.Z,;.IF;G:0$N-B# M(U'1DO*[>/[#RRCD3E*. 1'P;GLK=,QW%AAF&3A^-_5YJZ7B9WX^"1;G\VH^ MJ :@SP3DB@R.-+YKK+Y^]@LQRJ>KO8<3O4,5N M6+EF.(X;7;&:ZNU)!)FET-(^Z"'3(:4$/31,D6"ZG D%@DG%/@41E_LUD71Z M5Q>166(R?8RS#S68&R7-@/5 B\U>- [C0+NIH6"1DBKB%CQVQC*$[ M>A^Y@_=/HCOB? 3]GUTL8P%8;P$BE]P7 5/&^N*8-^ G+RNL,&_B&NDIR2Y.EA M%OS7*349=W5';/Q>6/B"L@VUNQ=T#VT!VA ZE,/"/6N%5"B25.^=C@^RAGDW[7XFDS M>$H- ]! 83?(5OO^>>,';R6"G,X?0J!K@."INND UBH3*?")WK!L "#S,,; M'3#(5LFS*^YU".2AA\=>9"CTIHZ(AE\8=X2#-?Q7,!!8D8X1GM?L?P-B#W%&*M$.S@I?6\$R4 SW] PK4.^0@@N?\WO96PPP=9#;QJ!\$ M(J>B[YX7*\R$Y[CZB8#/!V70\8 '%(IH-)U_*Q#=>&? M?X,-*+V]]=TCLCX.+K3AT6V!I)3\+J(7'!:PPHMR6LQR/-'*2IYLD1T\3"1+ M1Y.AXGOF:'=/X,Q&%@0K'&G9Q7/AR.1)U^TMB+TFTIK)!>)J00!E!^0'")H] M(=0DZ.*A4&L2) &X:9*S8+]_YCKC]A8F.GLH.70@5CD1]&A$U9X5?0(J9$[G M%G(>%K[0TKUH3RQ>$*WG:BJ^/ N4P1P:0PCU4J0,PFQ-CJA$5 _SQ*YK&QKO MHU[B&OI:!W2J4$AE/#I!CXIKVWC_<(:=>+ &.2%.U01'TP$,Z"B#K+(S1G7P ME6A]:=VGL(7(,LV8O'(K1,- ,H HZ%ZVM]"QA ^_A2F\AT5&-"00^W= BQCD M%"KQY1ZE6O5E7F@-!.J6R3TC,0G4#^.B]+W)I8PA2@=W.S^AOSCRA%UUC7; M(@BA%:-!OK@'T-.M.*PB+ 9UF+ 6CU29X4-0OI@&9P%]2\6G2K.]%5]AB-65 M:-=8%=J;5$$&5 4[)6(S[!@R4FB@4##-[A[624 QP-R"L3*[ O4>,\#!Z]$[ M%F C9Z+L1>(,W>5OK^4/:S=@\%"=#U2=80U0+J%.$MLWECT/R0LM22&%YTG?V"?; M+![30%6Q7I6OAOO5,ZMF933V#^?-Q M6X4?86/@-!KF'+\6"?E[KC(LN;[#[+K75V5YB>?S0U8)C2KR7L3D# M.9N5Y$)!E1_9J%!(9E)]9[#.]:!GGZR KG019>6+";]U8=$@->KM]X2+5:=! MMS1YKT.4$NOBY]I6E9%R*]VE?#^GUH9R!8ALBWH9)-I #JJ(ZS%5ZE#ODNP. M\D#%Y %3/@@XD%-U\<98@J^,):K_4@[<;]FL[7^MK+/4ZS76.V%DJE>*C_)_ MBX^;*#Z^QAR?*_Z;\=:[<3/K_3:R.S2Q31L&WRFUZF>-N2[X[:$[V:T?TUU8643*$N%Y44C?M5-YP'LC8. M*X4&TWOM2X=!-M?%M T!B7S5[X"IHXMYK@!'7:=OVF"0U0UN5Z^4I"T,=FBAVSE)R#-A?L?4U:7FJ97/+FKD^FNY>5FN MU&[:]4KYHK5'ZHU*:B[.>.=RE\8E-A3X^!+GWZNP6>9-9"6/HO):?+,Z1 #X M95Q<*NV(?0GI2K/E<#J2YFG24@ H:5,;FKN_CY+KH=ZZH&R$")H#_90UK>)/ M :OT-=8EM% S_XYSLHL#DE< W>T2N1"+.B^2"T/QN/.WU\5O7.FO]0>[DX?'NS<0_W>TEK? MG79=:8ST 1N.#IXMI]:M'_X87SJ\VFN==NTOEQ>-P[MSY4'.%/Y.'Y3U\GFU MUS3D/'VJ?Q^XA;.-^J%64ZJ-[V?ZT_-9;?_FH7;_2]+9KQ_ZW: @?5&? M[_A9XUD^K]ZGK\Q6X<7ZIKO6_5WVMJR:#[S\;+Y-N^_ M9 9WVO//^[;6NFM?= =WV<8O8_#\XS:C?;UP6#^=D_YN-!O?E-[)B4>2_P-0 M2P,$% @ -C]I5UP:E<&9#0 Y"P !8 !T;3(S,S R.3ED,E]E>#DY M+3$N:'1MW5IM<]LV$OZN&?T'G#_DTAE)MN6DC2W54]F64S=^J^4T]7VY@4A( M0DP2#$!*47_]/0N %"G)3:Z7F?-=9C*60&*Q[_OL0OV?[Z\NCYN-_L_#P1G^ M,OK7O[^XOQP>]W?=7SS=]8_[)S=G#VQT_W Y_'%GHI+LB.WOI1F[E[$P[%HL MV)V*>=)R"RTV$EI.=K 16V^+?3'74YD MR2F^:CF=93O'_9/CX>>9',N,'1YV]ON[)\=_0N+I4[Y6@#H3D9AD/>;(MS.5 MXHATM6!9M(S[A;'*,A7;E\#Y^?4F#_8NKMVQT=_KC3A9W M#P[VNH>'8?>?XO/A87M?QM.]O?W.QW2ZPP:7]S_N#%@J@RS7@@4X@LM$)E,6 M1#+E.F/L3)A RS23*F%3D0C-,Q&RA;F[/3RXOR\V;@28#'IF6>_,B"3KLY34W(?]TQ(9O[W[_CKU\$86?,>2#A8PB-A8L)(.2VX,8TR(2W BF M)GC%8(FL_*EJ9;VR,I/)7)A,Z68C6)D;HD0MEFHQERHWT9*98";"/$+D3(AE MX@I:G.7:V$];]=3!"_ <)Q$+<@W:64320%>(S@PVF<@(;#<;W.T\5SIVG_:[ MXW;WM5?GM]I'>]V8E(LT%4"LNW+/OBO:[K4\B#(B/C^X<&KSO]EJJAX=+.AQ:=<(I98K%!\,KQ( MNJ:@P?940;F9Y!'CX'4^_/W! M1_L++::]E2U=R)2NX$T$?^@T&Q<)3@LE&;EEZ1?15W$DXL\X5ZH$>"A-$"D# MTUOGG.1(+$O!-9OF,N24$T*U2!9/I!F8T"!LK(C7296(R9#&IHB M6T#/*M>L#'V*-RPT&RK/(J4>;3Q#&:]<*"X$*U9)"TZ3I?$22RM DA$Z(*/3 MDXF*I*(H5%--)_BW4ID*F%"X$\&3!F^P&1P#J;CE,T"S83(+548!(!6[YQKR M3EKL%J2<0+3]='A#@MB:\JP- ^Q1AQOG<#CHZ8%\S+K%=!#H+YX?_!S,9R*.8B4BD5BA;U+PF] MWP*323[AU.!0IJ$7*VF&\CI2D!$=5C!A'\L,1S<;<"-/U98,N-/<9AD6BQ 8 M#'G/04GGAI0B8\$I"B$%DS'! >$*%QX!L4GZ_$(;BUTC2E?^7+]F*KS)/TAX MK<(\( >721#EH2AJFRUJ+7;W,+B^.1O^[K^>#*_/AN\&Y;?+N\'M/V[\U_N[ MX>#=Q>CARA7$E[]P*-(#I9.'\\%O[D7W?7#W\_!J]#!R2]E,JWPZ Q<093%3 M9"*4,S!H\C'2J>3H! ?YF%\'795!*H2$V7+O->CW9CD?$QDGS D)" MUKP<4*#,\%YH4^@!CY-0$J2$1DK,NH(*L!?JMRT6%F@9H>=@DFH$3ZT',=#G M*%:!5G@IAM5D"K.C?%O,;VN&<3HATH6WP2TF*LBIOJ,*K7RBV5AYPG9^Q@(T ML$;-M,>-<#FC$F_A8C^]P4,YCD8">3% ^8P="P1*?:?&@M3?VFU4/!&% M1^R63T4/[W_*J<2!+&NW_2BJ?W;Q6WV@XR8N^]W*R*68L'Q/:V.EX2;EVDG$ M@T>VC\,-W#($ YL#(AK,K 3M[^+,+<>/X6:/[;& OC+ GYCR@&!'Y>9H@OU MT+8=>>%,*5R)22E'>"#M*T61%&ZUG%.K7&D++_%GZH+]CAPI7O6'AZ^1HY M8ML>MRI0V*SV1WS18>=/,H5JJT7ENRMEM):HC$'<3&F;DZEZHE!]0*PXF)_. M-.0W2/Y4>DOY5X.)L$#A:ZI97R:\MP+LY:K*HXU7@VV+,5^N+[F^97VU3,D; M#]"$0.3U9=?OK>18,3=&94+ZWZ 3\8U#$\+FDYQ&J^N/+)7)^FK1*Y;KI&PC M@:% ""R1]\$;O.4((]GA"*J,[6CD9,F>]D$[3C(U@_ORVD(3MS)\A/,R2[76 M I>%Q:G&NF51A,$7K15-.1"X=VR""Z/AJ>^Y$5ONQ&+2MCZN*LMNO3%?E>.* MAU7&=,W&1D/P=<,D=T0Q46K51&/;)*N?7QD]E S -."U;(H].U7!2U=TIU>F M&V[!CCB<59^8<)!LQ8AC]/[6#3CZN_31J:H6X^48S,N%E^$@A0G6K;O2)"#7 M1^RR>XA(Z9P56:KZJ.P4VL(4ZD#]$."@!3"]-CW8=GRAN-87NOS2(U98ZPF* M-3H>1E*[6.#(;X49@=,BRX1-BI4@LTDV'W_T;@1<1T6#:6D>O7FH1;6+E+5M MP[(D0HN9I/2JZ:3)1 ;488 L@ 0HQM?N L90N-CL51>)>L:H#*E5=1R^=WF M42!+8%E&75&UB:9V!T=!U3$->*6E/-$JQE9E1)&"!$V]6S1[1XN#/!;21^\N M=O;I$L=Z*JJ"U[J7=MB(E/:42KZ4IX[L<>"%ZE0)LI7)VNSTYK>+L_;^(2)_ M+K5*XF+P,Q4J!<3+R@*G]*J>V2L%FGRA-0'%L<@60J (YTB_W&Y__ZAYX51O M^1]N\<)H+J*>NTT@& ^U3(#0Z6H-JE5C9W@QS1'A"AT33ZE#W/#=OQNK6QHP M(FW!PD7+: ?,:WV04V4>!# ,=9W4L432QI[-8.=G@Q8;YEJEP!OLJNQ6!O"= M8%F)KBEZ56T59%W",NF"/P7!@-H,YWX^A KF38^YZ;4I1H05"2MJ[]EG=4COX0]+U$!'"LII5I\A0145^."R VZ/(UCI]]%I^9+NN0,>7I[!I M"3=QAAYF,O5%H6H9MUOE&75Y:,,F+%JA-IG,531WB7)9U,.BI7=W5XA(@!@V MXW-R)N_$S$;(QHY>?0!K,SO%5"#X& 4V6WKNZ>:QG@((*D21<.&>DB]HO&TO MGST?HOPV\363))2D'O(HD=D6U"4#YR]KW*$F<_@H9WX@ T_ M"F(99302J+; 7)N,2C?WMSN$$Y P(YLLM"L2!32.U**X^2HXZ7GU(7F!X1F- M7NTH*-3YM#J4OES-Q@VDBTLJ!1!7Q:M ME_J0W'IJS[LZ54MGRBW5S&%U:TUE$.^9R*H M]]"WR[+7LY&FZ[!'9*V78+7+U^!<0O;]SQZ(I& MLNX(0M4.6V\SP/I]L-F0HKP5;C;J&+YRAA?C8%,,=!Z6G67M7MUAY$([=;*_ M(,&L=P5UJLV&)SO(IP#N[N4W51G_@,@)4E0RH$(S%DZ)"/H*U:799G-GFZ&UY['Q[Q1?U.U:+MC#\B M)!)"1U%1-D$C3^UQZUC:7AI.J) QY-5R9J$H^=B<%D@=Y#%V0%?^H?@L35;] M4<)V.9@5XSE/H/HGQQ?^QR9PG *=D1]_Z>+HZ!L/URZEX>RJPS[(R*CD&Q*^ M2-HCJL:49_+$_V*E?@7V[09Z1ZR[WVV_>MUM=W\X/'@6]V!'E5E]M+#:_4DF M!% 0LLMB9/^LG?0O_V3QY/@V1PX(FHV_Y-Q.;2=WQU1!*HHQKM6Q_0!)T MZ[#XF_T?VF_VZ/^K5VZ1=/[^>$);?EJ[&GG6>OZ*FY%NC]W8'VZ:(W;)D02? MS47)?^'6XND?^.[2KY3=SY;IU\W_ E!+ 0(4 Q0 ( #8_:5>/ :!8)P, M . + 1 " 0 !E9W)X+3(P,C,Q,3 Y+GAS9%!+ 0(4 M Q0 ( #8_:5=%@^(Q_0H ("& 5 " 58# !E9W)X M+3(P,C,Q,3 Y7VQA8BYX;6Q02P$"% ,4 " V/VE7[B07B%0' #35P M%0 @ &&#@ 96=R>"TR,#(S,3$P.5]P&UL4$L! A0# M% @ -C]I5TZF#DY+3$N:'1M4$L%!@ % - 4 20$ "DX $! end